AbbVie (ABBV) Q3 FY2026: Revenue and Earnings Increased, Alongside Higher Debt
AbbVie (ABBV) Q3 FY2026: Revenue and Earnings Increased, Alongside Higher Debt
Opening
AbbVie's third-quarter fiscal 2026 revenue and earnings increased from the prior year. Revenue rose 10.3% to $17.404 billion, while operating earnings increased to $6.267 billion from $1.904 billion. Lower acquired in-process research and development and milestone expenses contributed substantially to the earnings increase. Operating cash flow also increased over the first nine months, although debt rose alongside cash balances. The filing contains financial statements and explanatory notes, allowing these changes to be assessed.
1. Consolidated Balance Sheet Analysis
1-1. Comparison of Major Asset Categories
The balance sheet shows what a company owns and the obligations it must meet at a particular date. The comparison is between December 31, 2025 and September 30, 2026.
| Item | December 31, 2025 ($ millions) | September 30, 2026 ($ millions) | Change | Interpretation |
|---|---|---|---|---|
| Cash and equivalents | 5,229 | 10,774 | +106.0% | Higher cash balances; assess alongside debt maturities |
| Accounts receivable, net | 12,589 | 13,509 | +7.3% | More sales proceeds remained to be collected |
| Inventories | 4,951 | 5,305 | +7.2% | More cash was tied up in inventory |
| Property and equipment, net | 5,628 | 5,941 | +5.6% | Net carrying amount increased; this is not capital expenditure |
| Intangible assets, net | 52,641 | 56,652 | +7.6% | Acquisition additions increased assets while amortization reduced them |
The filing reports these balances in millions of U.S. dollars. No Korean won conversion is presented because a conversion exchange rate has not been specified.
Cash should be assessed alongside debt maturities. A higher balance does not by itself mean operations generated more cash if the money came from new borrowing. Accounts receivable represent sales proceeds not yet collected. Assessing collection pressure requires checking whether receivables have grown faster than sales.
Inventory should be assessed to distinguish preparations for higher sales from goods whose sale has been delayed. Property and equipment should be considered alongside asset purchases and depreciation. Note 6 explains that the increase in indefinite-lived intangible assets primarily reflected the Apogee acquisition, which added $9.1 billion of acquired in-process research and development. Intangible amortization was $5.106 billion for the first nine months of 2026, and the cash flow statement reports no intangible impairment adjustment for that period, compared with $847 million in 2025. Impairment reduces an asset's carrying amount when the amount expected to be recovered from it has declined.
1-2. Liability Structure — Financing Liabilities vs Operating Liabilities
Borrowings provide financing for the business. The filing discusses senior notes, commercial paper, short-term loan facilities and revolving credit facilities. However, a facility's limit differs from the amount actually borrowed. Short-term borrowings, the current portion of long-term debt and long-term debt totaled $80.903 billion at September 30, 2026, versus $67.496 billion at December 31, 2025, an increase of 19.9%. This total uses balance-sheet carrying amounts and excludes undrawn credit commitments.
Operating liabilities are obligations arising from purchases or other business activities. Accounts payable and accrued liabilities totaled $34.429 billion at September 30, 2026, compared with $34.734 billion at December 31, 2025. This combined line should not be treated entirely as trade payables: Note 7 also places certain derivative liabilities within it. Provisions likewise require examination of their underlying obligations before classification.
Assessing funding pressure requires near-term repayments, cash balances and available credit facilities. At September 30, 2026, the current portion of long-term debt was $8.673 billion, cash was $10.774 billion, and two revolving facilities totaling $8.0 billion were undrawn. Debt increased by $13.407 billion from year-end, exceeding the $5.545 billion increase in cash. These figures show a larger debt burden alongside available liquidity; the undrawn facilities are borrowing capacity, not cash.
1-3. Equity Structure
Paid-in capital represents capital contributed by shareholders and consists of common stock and additional paid-in capital. Retained earnings represent accumulated profits that have not been distributed through dividends or other outflows.
The filing reports common stock, additional paid-in capital, an accumulated deficit and treasury stock. Common stock plus additional paid-in capital totaled $23.389 billion at September 30, 2026, versus $22.513 billion at year-end. The accumulated deficit widened from $15.493 billion to $16.190 billion because dividends declared of $9.223 billion exceeded net earnings attributable to AbbVie of $8.526 billion. Treasury stock at cost increased from $9.146 billion to $10.616 billion, and total stockholders' deficit widened from $3.270 billion to $4.583 billion. These are disclosed balances; the negative equity total makes conventional positive equity composition percentages unsuitable.
2. Consolidated Income Statement Analysis
2-1. Comparison of Key Earnings Measures
Quarterly results should compare July–September 2025 with July–September 2026. Mixing these with the January–September cumulative periods also shown in the filing would distort growth rates.
| Item | Q3 2025 ($ millions, except margins) | Q3 2026 ($ millions, except margins) | Change |
|---|---|---|---|
| Net revenues | 15,776 | 17,404 | +10.3% |
| Operating earnings | 1,904 | 6,267 | +229.1% |
| Operating margin | 12.07% | 36.01% | +23.94 percentage points |
| Consolidated net earnings, including noncontrolling interests | 188 | 4,220 | +2,144.7% |
| Consolidated net margin | 1.19% | 24.25% | +23.06 percentage points |
Operating margin is operating earnings as a percentage of revenue. Net margin measures final earnings after interest, taxes and other items as a percentage of revenue. Changes between periods in these margins should be expressed in percentage points.
The filing provides cost of products sold, research and development, and selling, general and administrative expenses, together with explanations of revenue drivers. Third-quarter revenue increased 10.3% as reported and 10.5% at constant currency. Management attributes Skyrizi and Rinvoq growth primarily to market share gains and market growth, while Humira declined because of biosimilar competition. Acquired in-process research and development and milestone expenses fell from $2.680 billion to $216 million, accounting for $2.464 billion of the $4.363 billion increase in operating earnings. Net interest expense of $700 million and other net expense of $738 million reduced operating earnings of $6.267 billion to pretax earnings of $4.829 billion; income tax expense of $609 million left consolidated net earnings of $4.220 billion.
2-2. Fixed Costs vs Variable Costs
Fixed costs do not change substantially with sales volume over the short term. Variable costs change with production or sales volume. However, cost of products sold can include factory depreciation as well as raw materials. Selling, general and administrative expenses can likewise include both fixed personnel costs and variable sales commissions.
Research and development expenses should not be classified entirely as fixed costs either. Spending can vary with development stages and contractual terms. The filing does not provide a comprehensive allocation of expenses between fixed and variable costs.
When fixed costs grow more slowly than revenue, fixed costs per dollar of revenue fall, potentially improving profitability. This is operating leverage from fixed costs. AbbVie's management attributes the gross margin improvement partly to higher revenue relative to lower fixed costs, primarily from reduced intangible amortization. The comparison also benefited from $847 million of intangible impairment charges incurred in the third quarter of 2025. This supports a fixed-cost contribution to the improvement, although the filing does not quantify a complete fixed-versus-variable cost split.
3. Cash Flow Statement Analysis
Cash flows show actual cash receipts and payments. The comparison should use the cumulative January–September periods for both 2025 and 2026.
| Item | January–September 2025 ($ millions) | January–September 2026 ($ millions) | Change ($ millions) |
|---|---|---|---|
| Operating cash flow | 13,812 | 14,871 | +1,059 |
| Investing cash flow | (5,180) | (11,986) | (6,806) |
| Financing cash flow | (8,558) | 2,685 | +11,243 |
| Cash and equivalents at September 30 | 5,629 | 10,774 | +5,145 |
Operating activities require attention to income tax payments and changes in receivables, inventories and payables. Even when a company reports an accounting profit, cash inflows can be smaller if customers have not paid or cash is tied up in inventory.
Investing activities should distinguish capital expenditure from acquisition spending. Financing activities require examination of new borrowing, debt repayments, dividends and share repurchases. For the first nine months of 2026, the filing reports $888 million of property and equipment purchases, $10.594 billion of business acquisitions net of cash acquired, and $1.356 billion of other acquisitions and investments net of cash acquired. Financing cash flows include $17.974 billion of long-term debt issuance proceeds, $2.0 billion each of short-term borrowing and long-term debt repayments, a $499 million net reduction in commercial paper, $9.227 billion of dividends paid and $1.503 billion of treasury stock purchases.
Free cash flow (FCF), defined here as operating cash flow less capital expenditure, was $13.983 billion for the first nine months of 2026: $14.871 billion minus $888 million. The comparable 2025 amount was $12.927 billion: $13.812 billion minus $885 million. FCF therefore increased 8.2%. Using all investing cash flow as a substitute for capital expenditure would include acquisitions and other transactions and produce a different result.
4. Additional Analysis This Report Must Address
The following four matters are covered by the filing's financial disclosures and explanatory notes. Their disclosed amounts and business effects can therefore be examined.
Major Products' Contribution to Growth
The filing provides product and geographic revenue figures for Skyrizi, Rinvoq and Humira. Third-quarter worldwide Skyrizi revenue increased from $4.708 billion to $5.776 billion, Rinvoq increased from $2.184 billion to $2.706 billion, and Humira declined from $993 million to $683 million. The respective changes were positive $1.068 billion, positive $522 million and negative $310 million. These reported sales figures, rather than the presence of product names, establish their contributions to revenue growth.Costs and Cash Requirements of Acquisitions and Collaborations
Note 4 describes the Apogee Therapeutics and Nimble Therapeutics transactions. AbbVie acquired Apogee on September 3, 2026, for consideration of approximately $10.6 billion, or $10.5 billion net of cash acquired, and accounted for it as a business combination. Separately, it recorded $318 million of cash-settled post-closing employee award expense in the third quarter. Nimble's January 2025 acquisition price of $288 million comprised $210 million of upfront cash and $78 million of acquisition-date contingent consideration fair value. The agreement provided for up to $130 million of development milestone payments, and the filing states that the contingent consideration liabilities were paid in the third quarter of 2026 after the milestones were achieved. Purchase consideration, expense recognition and cash payments are therefore distinct.Management of Interest Rate and Currency Movements
The filing discusses foreign exchange forwards and interest rate swaps used to manage currency and interest rate exposures. Note 7 provides their notional amounts, fair values and recognized gains or losses. At September 30, 2026, foreign exchange forwards designated as cash flow hedges had $4.6 billion of notional principal. Interest rate swaps designated as fair value hedges had $7.8 billion of notional principal and converted fixed-rate obligations to floating rates; cash flow hedge swaps had $750 million of notional principal and converted floating-rate obligations to fixed rates. The existence of these contracts alone does not establish that losses were prevented.Litigation-Related Payment Obligations
Note 11 discusses prescription opioid and product liability litigation. Litigation status, recorded provisions and expected payment timing should be distinguished. Recorded litigation accruals were approximately $1.3 billion at September 30, 2026, compared with $1.6 billion at December 31, 2025. The company states that it cannot estimate possible losses or ranges beyond accrued amounts for the matters discussed where losses are probable or reasonably possible. The disclosed accrual is therefore not an estimate of all potential future litigation payments.
5. Key Implications and Outlook
The disclosed results support an assessment of stronger revenue, earnings and operating cash generation, alongside higher debt. The earnings increase also reflects lower acquired in-process research and development and milestone expenses and the absence of the prior-year intangible impairment charge, so it should not be attributed entirely to sales growth. The variety of products and financing arrangements alone does not establish growth or financial stability.
The favorable scenario is that growth in major products translates into higher operating cash flow while the company retains the capacity to meet debt obligations after investment and shareholder distributions. The risk scenario is that costs and payment obligations grow faster than cash generation. The first nine months show higher operating cash flow, but also substantial acquisition spending and increased debt; the outlook depends on subsequent product sales, spending and payment obligations.
Source: AbbVie Inc., Form 10-Q for the quarter ended September 30, 2026, filed November 3, 2026. Financial statements appear on pages 1–5; relevant disclosures include Notes 4, 6, 7, 11 and 12 and Management's Discussion and Analysis. Amounts are presented in U.S. dollars without conversion to Korean won.
Disclaimer
This report is based on AbbVie's Form 10-Q filed with the U.S. Securities and Exchange Commission and is provided for informational purposes. It is not an investment recommendation.